5143, E-mail: mirek@bri.nrc.ca Over the past decade, antimicrobial resistance has emerged as a major public-health crisis. Glycopeptide antibiotics (GPAs) such as vancomycin and teicoplanin are clinically important for the treatment of Gram-positive bacterial infections. StaL is a PAPS-dependent sulfotransferase capable of sulfating the cross-linked heptapeptide substrate both in vivo and in vitro, yielding the product A47934, a unique teicoplanin-class glycopeptide antibiotic. The sulfonation reaction catalyzed by StaL constitutes the final step in A47934 biosynthesis. Here we report the crystal structure of StaL and its complex with the cofactor product PAP. This is only the second prokaryotic sulfotransferase to be structurally characterized. StaL belongs to the large sulfotransferase family and shows higher similarity to cytosolic STs than to the bacterial ST (Stf0). StaL has a novel dimerization motif, different from any other STs that have been structurally characterized. We have also applied molecular modeling to investigate the binding mode of the unique substratedesulfo-A47934. Based on the structural analysis and modeling results, a series of residues were mutated and kinetically characterized. In addition to the conserved residues (Lys12, His67 and Ser98), molecular modeling, fluorescence quenching experiment and mutagenesis studies identified several other residues essential for substrate binding and/or activity, including Trp34, His43, Phe77, Trp132 and Glu205.
Over the past decade, antimicrobial resistance has emerged as a major publichealth crisis. Glycopeptide antibiotics (GPAs) such as vancomycin and teicoplanin are clinically important for the treatment of Grampositive bacterial infections. Moreover, vancomycin has been commonly termed a "drug of last resort" for treating lifethreatening infections by Gram-positive pathogens, many of which are resistant to most other antibiotics (e.g., methicillinresistant Staphylococcus aureus) (1;2). However, the increasing prevalence of infections due to vancomycin-resistant S. aureus and Enterococci have resulted in elevated rates of morbidity and mortality (3;4) . This serious and growing threat has driven the urgent need for novel antibiotics, including diverse semi-synthetic derivatives of members of this class.
Glycopeptide antibiotics are comprised of a heptapeptide core containing both common and unusual amino acids. Based on the identity of the core peptide, GPAs can be divided into two major structural classes exemplified by vancomycin and teicoplanin, respectively. The structural diversity of natural GPAs is mainly derived from enzymatic modifications of the core peptide by a variety of halogenase and glycosyl transferase enzymes (2;5) . Streptomyces toyocaensis NRRL 15009 produces A47934 (6;7), a unique teicoplanin-class glycopeptide due to two reasons: (a) it is not glycosylated, albeit it contains the characteristic heptapeptide core and is therefore an "aglyco"-glycopeptide antibiotic and (b) it is sulfonated on the N-terminal 4-hydroxyl-Lphenylglycine (L-HPG) residue, resulting in its overall negative charge at physiological pH.
Naturally occurring "aglyco"-glycopeptide antibiotics are rare since they are converted to their glycosylated form by glycosyltransferases encoded by the producing organism. However, S. toyocaensis lacks glycosyltransferase-encoding genes in the A47934 biosynthetic cluster (8) and as a result exclusively produces A47934, an attractive and proven scaffold for novel antibiotic development both in vivo and in vitro (9) .
Sulfonation of biomolecules has long been known to take place in a variety of organisms and new biological functions continue to be uncovered in connection with this important transformation (10) . Sulfotransferases (ST) are a superfamily of enzymes found in species ranging from bacteria to humans, catalyzing sulfonation of a variety of endogenous and exogenous substrates. While the substrate specificity of individual sulfotransferases differ significantly, all utilize the ubiquitous sulfate donor cofactor, 3'-phosphoadenosine 5'-phosphosulfate (PAPS) (10;11) . Studies of this enzyme class have been most extensively performed in eukaryotes (12;13) . The eukaryotic sulfotransferases are grouped into two major classes: cytosolic STs and membrane-associated STs, which share less than 20% sequence identity and differ in terms of their solubility, size, subcellular distribution and substrate specificity (10) (11) (12) (12) .
In contrast to a large body of knowledge accumulated on mammalian sulfotransferases significantly less is known about the pervasiveness and functions of STs and their sulfated products in bacteria (13) . So far, there are only a few bacterial PAPSdependent sulfotransferases for which the biological significance has been well established. The sulfotransferases NodH and NoeE of Sinorhizobium meliloti are essential for establishing symbiosis by sulfonating secreted root lipo-chitooligosaccharide signals, called nodulation factors (17;18) . The enzyme Stf0, a novel mycobacterial sulfotransferase from Mycobacterium tuberculosis has been identified and characterized, and is responsible for generating the trehalose-2-sulfate moiety of the putative virulence factor sulfolipid-1 (19) . Meanwhile, the crystal structure of Stf0 from Mycobacterium smegmatis, the first from a bacterial source, has also been determined. This structure revealed the molecular basis of trehalose recognition and a unique dimer configuration that encloses the substrate within a bipartite active site. Very recently, a sulfotransferase LpsS from Mesorhizobium loti has been identified to be involved in sulfonation of cell surface polysaccharides, including LPS and capsule (20) . As well, the sulfotransferase Stf3 has been recently identified, which sulfonates an outer envelope molecule in Mycobacterium tuberculosis involved in mediating virulence in a mouse infection model (21) .
StaL (GenBank accession number AAM80529) has been annotated as a putative PAPS-dependent sulfotransferase from analysis of the A47934 biosynthetic gene cluster sequence (8) . More recent genetic and biochemical studies have confirmed that StaL is a sulfotransferase capable of sulfating the predicted cross-linked heptapeptide substrate both in vivo and in vitro, yielding the A47934 product. The sulfonation reaction catalyzed by StaL constitutes the final step in A47934 biosynthesis ( Fig. 1) (22) . In addition, incubation of purified His 6 -StaL with various substrates in vitro revealed its substrate specificity and yielded two novel sulfoglycopeptide antibiotics: sulfo-teicoplanin aglycone and sulfo-teicoplanin (22) . This sulfonation adds to the expanding repertoire of engineering possibilities for glycopeptide antibiotics with the potential to develop new compounds with sulfated N-terminal 4-hydroxy-L-phenylglycine residues. Here we report the crystal structure of StaL and its complex with the cofactor product PAP. To our knowledge, this is only the second prokaryotic sulfotransferase, following the structure of Stf0, to be structurally characterized. This structure reveals that StaL is most similar to the cytosolic STs from mammalian sources and less similar to bacterial Stf0. StaL adopts a unique dimerization motif, different from that of all other STs for which crystal structures have been solved. We have also applied molecular modeling and site-directed mutagenesis to investigate the binding mode of the unique substrate -desulfo-A47934.
EXPERIMENTAL PROCEDURES
Cloning, expression and purification -The staL gene from Streptomyces toyocaensis was cloned into a modified pET28a vector (EMD Biosciences, Inc.) and expressed in E. coli BL21 (DE3) fused to an N-terminal (His) 6 tag, as described previously (22) . The gene was cloned starting from the second ATG and is missing the first 3 codons. Therefore, the expressed StaL has 267 amino acids (excluding the His 6 -tag) and lacks the Nterminal Met-Asn-Gly sequence. For the production of selenomethionine (SeMet)-labeled protein the E. coli methionine auxotroph strain DL41(DE3) was transformed with the plasmid (23) .
An overnight culture of transformed E. coli BL21(DE3) or DL41(DE3) was used to inoculate 1L 2YT medium (or LeMaster medium for SeMet labeled protein) containing 50 µg/ml kanamycin and grown at 37°C until the absorbance at 600 nm reached 0.6. Protein expression was induced with 1mM isopropyl 1-thio-βD-galactopyranoside (IPTG) followed by 16-20 h incubation at 16°C. The cells were harvested by centrifugation (4000xg, 4°C, 25 min) and stored at -20°C. The cell pellet was resuspended in 40 ml of lysis buffer (50 mM Hepes pH 7.5, 0.5 M NaCl, 5% (v/v) glycerol, 20 mM imidazole pH 8, 10 mM β-mercaptoethanol, and 0.5% (v/v) Triton X-100), and the cells lysed by sonication (8 × 15 s, with 15 s between bursts). Cell debris were removed by ultracentrifugation (100,000xg, 45 min, 4°C). The protein supernatant was loaded onto a 2 ml (bed volume) of Ni-NTA resin (Qiagen) equilibrated with lysis buffer. After application of the protein sample, the column was washed with 40 ml of lysis buffer, followed by 40 ml of washing buffer consisting of 50 mM Hepes buffer pH 7.5, 0.5 M NaCl, 5% (v/v) glycerol, 20 Finally, we crystallized StaL (12 mg/ml) in the presence of 10 mM PAP and 5 mM desulfo-A47934 substrate. Hanging drop vapor diffusion over a reservoir solution containing 0.2 M NaI, 0.1M Bis-Tris propane pH 6.5, 18% (v/v) PEG-3350 yielded crystals isomorphous to form 3, which we will refer to as form 3b. These crystals grew in 2~4 days and were cryo-protected by a brief transfer to a solution containing reservoir solution supplemented with 15% (v/v) ethylene glycol and flash cooled in the nitrogen stream at 100 K. Determination of product affinity by fluorescence quenching -Steady-state fluorescence spectra were recorded at 25°C on a Spex Fluorolog 1681 spectrometer (Horiba Jobin Yvon Inc., New Jersey, USA). A cuvette containing 500 μl of protein sample was prepared at a concentration of 1.5 -3 μM in 20 mM Hepes, pH 7.5, 0.2 M NaCl, 5% (v/v) glycerol and 5 mM DTT. The intrinsic tryptophan fluorescence of StaL was measured by recording the emission spectra from 300 to 370 nm (2 nm slit width) with a fixed excitation wavelength of 290 nm. Fluorescence quenching experiments were performed by titration of the protein sample with a concentrated stock solution of A47934 dissolved in the same buffer as the protein sample. The concentration of A47934 was varied in the range of 8 to 135 μM. In order to eliminate inner-filter effects, the absorbance of the enzyme sample did not exceed 0.1 at 290 nM. The spectra were corrected for the intrinsic fluorescence of the A47934 product at each point in the titration.
To analyze the fluorescence data, the fluorescence intensities at various concentrations of the quencher were fitted to the Stern-Volmer equation for the quenching of emitting fluorophores (25) F 
X-ray Data Collection, Structure Solution, and
Refinement -Diffraction data from a form 1 SeMet-labeled StaL crystal were collected to 2.8 Å resolution at three wavelengths (MAD regime) with a Quantum-4 CCD detector (Area Detector Systems Corp., San Diego, CA). Unless otherwise indicated, this and all subsequent datasets were collected at beamline X8C at the National Synchrotron Light Source, Brookhaven National Laboratory. Data integration and scaling was performed with HKL2000 (26) . Seven out of the nine expected selenium atoms in the asymmetric unit were located with the program SOLVE (27) using data to 3.0 Å resolution. Solvent flattening resulted in a figure of merit of 0.61. The density modified phases were utilized with a dataset from a native crystal (form 1) collected to 2.58 Å resolution at beamline X25 and extended to the resolution limit. Automatic model building with RESOVLE (28) resulted in a starting model containing ~50% of the mainchain atoms and ~20% of sidechains. Remaining parts of the model were built manually using the program O (29) and refinement carried out using the program REFMAC (30) . No σ-cutoff was used in refinement. In the final rounds of refinement we applied the translation-libration-screw (TLS) model for anisotropic temperature factors (31;32) converging to a final R-work and R-free of 0.249 and 0.279, respectively. The N-terminal His 6 -tag and residues 104-109, 217-236 were disordered and could not be traced in the electron density map.
A dataset for form 3a crystals of StaL crystallized in the presence of PAP and ammonium sulfate was collected to 2.61 Å resolution. The structure was solved by molecular replacement with the program MOLREP (33) using the apo-StaL structure as the search model, and refined to a R-work and R-free of 0.228 and 0.269, respectively. Only the His 6 -tag and residues 217-235 were disordered. No density corresponding to PAP was found in the resulting maps, but instead, two sulfate ions were modeled in the PAPbinding site. We refer to this model as StaL-SO 4 .
Crystal form 3b of StaL crystallized in the presence of PAP and desulfo-A47934 yielded data extending to 2.95 Å resolution. The structure was solved by molecular replacement using the apo-StaL model and refined to an R-work and R-free of 0.224 and 0.269, respectively. The resulting difference electron density clearly showed the presence of a molecule of PAP bound in each subunit but no density for the antibiotic was found. The final model contained only one disordered segment, consisting of residues 217-235. We refer to this model as StaL-PAP.
The tetragonal form 2 crystals diffracted to 3.45 Å and the structure was solved by molecular replacement. We identified a dimeric association of the molecules similar to that observed in the hexagonal crystal forms but the structure was not refined further due to the inferior resolution.
Finally, the trigonal form 4 crystals diffracted to 3.05 Å at beamline X12C. There are 4 independent molecules and the model was only partially refined. Electron density indicates the presence of PAP but it is less well defined than in form 3b crystals. The form 2 and form 4 crystals diffracted to low resolution, showed dimers indistinguishable from those in better diffracting crystal forms and were not pursued further.
Final data collection and refinement statistics are shown in Table 1 . Site-directed mutagenesis -Oligonucleotide primers were designed using PrimerSelect (DNASTAR Inc.) and are listed in Supplementary Table 1 . Single site mutants were created using the QuikChange® sitedirected mutagenesis kit (Stratagene, La Jolla, CA) with modifications as described below. Synthesis of oligonucleotide primers and sequencing of DNA were performed at the MOBIX Lab Central Facility (McMaster University). Using the previously constructed plasmid staL/pET28a (22) as a template, PCR conditions were as follows: 5 min at 95°C, 16 cycles (1 min at 95°C, 1.5 min at 55°C, and 10 min at 68°C), 20 min at 68°C with 1 U Pfu Ultra® DNA polymerase (Stratagene), 25 or 50 ng template DNA, 2.5 mM dNTPS, and ~250 ng of each primer. Subsequent digestion with 10 U of DpnI (New England BioLabs, Inc.) for 1 hour at 37°C facilitated destruction of the template DNA. Mutagenized plasmids were then transformed into E. coli TOP10 (Invitrogen Canada, Inc.) by electroporation. Plasmids were isolated from the transformants and were analyzed by restriction enzyme digests and DNA sequencing. Plasmids containing the confirmed staL point mutations were then transformed into the expression strain E. coli BL21(DE3). Expression, purification, and characterization of StaL mutants -Expression and purification procedures previously reported for wild-type StaL (22) were used for each StaL mutant. Similar expression levels were observed for all mutants except L48K, L48E and H67A which exhibited poor expression. Following purification and concentration, in vitro reactions were set up for each mutant with 0.1 mM desulfo-A47934 as the substrate. Conditions were as reported previously (22), except that the final concentration of PAPS was 5 mM. Four time points were determined in duplicate for each mutant protein in order to obtain the initial rate (v o ). Full steady-state kinetic analyses were not performed given the significant substrate inhibition observed by this enzyme (22) . We therefore determined only v o of the mutants under the substrate conditions indicated.
Reactions were analyzed by reverse phase HPLC using previously reported conditions (22) . For each reaction time point, the total peak area was determined for the substrate (i.e., desulfo-A47934) and the product (A47934). The relative area of product was then expressed as a fraction of the total substrate present (10 nmol) and plotted versus time. The v 0 was determined by linear regression. For comparing the activity of the mutants, the initial rate of each StaL mutant was expressed as a percentage of the wild-type StaL initial rate (Table 2) .
Mutant proteins were analyzed by circular dichroism (CD) spectroscopy to confirm that mutation did not perturb global protein structure (Supplementary Fig. S1 ). Prior to analysis, the mutant proteins were dialyzed for three hours at 4°C in buffer (5 mM HEPES, pH 7.5 and 100 mM NaCl), followed by measurement of the protein concentration by the Bradford assay (34). An AVIV model 215 Circular Dichroism Spectrometer (AVIV Associates, Lakewood, NJ) was used to record the CD spectra. A 1 mm path-length quartz cell containing 300 μL of each protein sample (~0.25 mg/mL) was maintained at 25°C in a thermoelectrically controlled cell-holder. Data was collected every 1 nm with an averaging time of 5 seconds and are expressed as the mean residue ellipticity in units of deg•cm 2 /dmole. Molecular modeling of the StaL-PAPSdesulfo-A47934 complex -The PAPS cofactor molecule was constructed from the bound PAP, to which a sulfate group was linked in the conformation observed in the human estrogen sulfotransferase-PAPS complex (PDB ID: 1HY3, (35)). Residues Leu213 and Leu238 at the ends of the disordered loop 217-235 were blocked, crystallographic waters were removed, and hydrogen atoms were added and oriented to favor hydrogen bonding. The StaL-PAPS complex was conjugate-gradient energy-minimized using the AMBER force field (36;37), an 8 Å nonbonded cutoff, a distance dependent dielectric (4R ij ), and using AM1-BCC partial charges (38) for PAPS. Harmonic potentials were applied during minimization to constrain various regions of the complex to their crystallographic positions.
The structure of the desulfo-A47934 substrate was built starting from the crystal structure of A-40926 aglycone (Cambridge Crystallographic Data Centre ID: 134958) (39) that has the same backbone. Only minor modifications were required, i.e., desulfo-A47934 lacks the first N-terminal methyl group, and otherwise differs only in the positions of three Cl atoms. The Fast Rigid Exhaustive Docking (FRED) program (40) was used to generate and rank initial potential binding modes (poses) of desulfo-A47934 to the StaL-PAPS complex. The top-scored 10,000 substrate poses were filtered down to 500 poses of good shape complementarity and having the reactive hydroxyl oxygen within 4 Å of the sulfur atom of PAPS. All these substrate poses had several minor clashes with StaL, suggesting that some conformational change must occur in the putative binding site in order to accommodate the substrate. The retained complexes were energy-minimized using the SZYBKI program (OpenEye, Inc., Santa Fe, NM), with the substrate allowed to move as a rigid body while protein sidechains within 10 Å of the substrate and PAPS were flexible. The resulting 500 minimized poses were then scored for binding using our 
). The molecular surface was generated with a variable-radius probe (42) .
The StaL-PAPS-desulfo-A47934 complex with the best SIE-scored substrate pose was further optimized by AMBER energy minimization. The substrate, the cofactor, and the protein atoms around them were allowed to relax under a set of harmonic space constraints, while the distance between the reactive oxygen atom of desulfo-A47934 and the sulfur atom of PAPS was constrained within the 2.0-3.5 Å range. The space constraints were then lifted and the entire complex was minimized up to an rms gradient of 0.001 kcal/(mol . Å).
RESULTS AND DISCUSSION

Overall structure
We have crystallized StaL using either PEG3350 or sodium chloride at high concentration as a precipitating agent. Under both conditions residues 217-235 were disordered and could not be traced in the electron density map. This segment of polypeptide is rich in Gly residues (6 of 19) and probably requires substrate binding to be ordered. In crystals obtained in the presence of high salt (3 M NaCl, 0.1 M NaAc pH 4.6) one other region was disordered, residues 104-109.
Each StaL monomer has an α/β architecture. The core of the molecule is a three-layered α/β/α sandwich with a central four-stranded parallel β-sheet with the order β2-β1-β3-β4, a bundle of α-helices on one side and an α-helix and a distorted helical turn on the other side (Fig. 2) . The top of the β-sheet is covered by another α-helical bundle. The main features are characteristic for the Rossmann fold with the P-loop crucial for nucleotide phosphate binding. The P-loop following strand β1 contains the sequence Lys-X-Gly, where X is a residue having a small sidechain, which is a hallmark of the PAPS binding site (12) . A large cleft formed between the two helical bundles is readily visible in the molecular surface representation of StaL. A molecule of PAP is located at one end of this cleft while the other side is wide open and forms the substrate binding site. The disordered region 217-235 connects the segments located on opposite sides of this cleft and may act as a gate that controls access to the substrate binding site.
StaL belongs to a large family of sulfotransferases
Sequence comparisons clearly place StaL in the sulfotransferase family (PFAM PF00685, (43) 1AQU) . Despite the relatively low sequence identity between these two proteins (19%), the root-means-square deviation (rmsd) for 204 Cα atom pairs is 2.8 Å (rmsd for the core 142 Cα atom pairs is 1.5 Å). In general, StaL shows the highest structural similarity to cytosolic eukaryotic sulfotransferases and, somewhat surprisingly, is less similar to the previously solved prokaryotic sulfotransferase Stf0 from Mycobacterium smegmatis (PDB code 1TEX) (19) (only core 88 Cα atom pairs overlap well with rmsd 1.7 Å) with which it has a sequence identity of less than 15%.
The amino acid sequence of StaL lacks the N-terminal ~30-35 residues that are found in the sequences of some other sulfotransferases (Fig. 2c & 3) . In cytosolic STs this region consists of two β-strands and a turn followed by a second α-helix and a turn and covers a hydrophobic patch on the surface of the protein. Some residues in this region are likely part of the substrate binding cavity and contribute to the stable binding of small substrates in cytosolic STs. In StaL, the lack of this region creates a wider substratebinding site and is in fact a prerequisite for StaL to form its unique dimeric structure, as shown below.
In addition to the N-terminal region, sulfotransferases differ in the length and conformation of several long surface loops. In StaL these regions correspond to residues 50-62 (Fig. 2c, letter A) , 104-110 (letter B), 125-137 (letter C) and 180-185 (letter D). Part of the segment Leu44-Leu63 protrudes into the region otherwise occupied by the additional N-terminal residues of other cytosolic STs (Fig 2c) . The loop Gly125-Ser137 in StaL is longer than the corresponding loop in cytosolic STs and forms one side of the substrate-binding site (Fig. 2c, C) . There is also an insertion of several residues in the region Ser148-Ala157 of StaL relative to other cytosolic STs. However, the most substantial change in StaL is observed in the conformation of the loop encompassing residues Gly104-Asp109, which connects helices α5 and α6. In StaL this loop extends in a direction opposite to that seen in other STs relative to the base formed by α5 and α6 helices (Fig. 2c, B) . While in other STs this loop is directed toward, and contributes to the formation of a compact substrate-binding site, the position of this loop in StaL creates a more open substrate-binding site that is capable of accommodating a large antibiotic as a substrate (Fig. 2c) .
The region 217-235, which we predict covers the substrate-binding site in StaL, is disordered in the absence of substrate, as has also been observed in several other STs where this loop (Fig. 2c , letter E) is ordered only when the substrate is bound.
PAPS-binding site
In order to identify the PAPS-binding site we co-crystallized StaL with the PAPS reaction product PAP. We observed clear electron density for a molecule of PAP in crystals obtained from PEG-3350 in the presence of 0.2 M NaI (Fig. 2b) .
A strand-loop-helix motif containing residues 9 ) is disordered in StaL in the absence of the substrate, and such disorder has been observed in the structures of several other STs lacking bound ligands. For example, this region is disordered in the crystal structure of the human sulfotransferase SULT1A3 in the absence of substrate (46;47), but becomes well-ordered in the presence of bound substrate (48) . In SULT2B1a and SULT2B1b some residues within the Nterminal region, which is part of the substratebinding pocket and also required for activity, are only ordered upon substrate binding (49 When the crystals were obtained in the presence of 10 mM PAP and 0.2M (NH 4 ) 2 SO 4 we found density only at the expected location of the two phosphates and we interpreted these peaks as two sulfate ions. This observation suggests that PAP(S)-binding is dependent predominantly on interaction between its phosphate groups and the protein and was outcompeted by the high concentration of sulfate ions. A similar observation was made in the case of sulfotransferase SULT1A3 (46) . The binding of PAP causes relatively minor changes in the overall structure of StaL, with a rmsd of 0.80 Å for all Cα atoms superposing the apo-and PAP-bound forms of StaL. On the other hand, the rmsd between the StaL-PAP complex and StaL-SO 4 complex (0.48 Å for all Cα atoms) is less, suggesting that the binding of PAP or molecules mimicking the phosphate groups of PAP in the StaL active site induces small but measurable changes in structure.
Fluorescence quenching of StaL by A47934
StaL was titrated with increasing concentrations of A47934 in the absence of PAP. The tryptophan fluorescence spectrum of StaL was quenched by addition of A47934 (Fig. 4a) . The change of fluorescence in StaL arises likely from changes in the environment of one or more of the seven tryptophan residues in StaL. Fluorescence titration data fit well the classical Stern-Volmer equation and the Stern-Volmer constant (K sv ) is 0.021 μM -1 (Fig. 4b) , reflecting a moderate affinity (disassociation constant K d = 48 μM) of A47934 for StaL.
A47934-binding region and molecular modeling
Despite several attempts to obtain the structure of the complex between StaL and its substrate desulfo-A47934, either through cocrystallization or by soaking crystals, in the presence or absence of PAP, no density for the antibiotic molecule was observed. We therefore employed molecular modeling to gain insight into the possible mode of substrate binding by StaL.
Protein relaxation by minimization of the molecular mechanics force field-based internal energy was applied both during and after substrate docking, thus ensuring good structural quality of the modeled complex. The protein part of the resulting StaL-PAPSdesulfo-A47934 model is quite similar to the starting crystal structure, with rmsd values of 0.56 Å, 0.65 Å and 1.05 Å for the Cα, mainchain, and all atoms (including PAP), respectively. These rmsd figures include relatively larger deviations experienced by only about a half-dozen residues located either at the ends of a disordered loop (217-235) or interacting directly with the substrate. The geometry of the modeled bound substrate, conformationally restricted due to intramolecular cyclization (see Fig. 1 ), is also close to its initial structure, with an rmsd of 0.53 Å for all its 83 non-hydrogen atoms. The good quality of the refined model of the complex is reflected quantitatively by its large SIE binding affinity score (eq. 2) of -12.2 kcal/mol, predicting a dissociation constant of ~1 nM of the desulfo-A47934 substrate from StaL-PAPS. This is a plausible value, given the moderate measured affinity (48 μM) between the A47934 product and apo-StaL derived from fluorescence quenching experiments. A qualitative analysis also indicates that the modeled complex exhibits good intermolecular physico-chemical complementarity. The cup-shaped desulfo-A47934 molecule is snugly situated in a pocket, with its concave surface packing against the N-terminus of helix α1 (residues [15] [16] [17] [18] [19] [20] and the PAPS molecule (Fig. 5a ). It is stabilized by four adjacent α-helices (α2, α3, α5, and α12) and the loop connecting helices α6 and α7. The convex surface of the substrate molecule is exposed to the solvent and, presumably, the missing loop (residues 217-235) may help to lock the substrate in the pocket.
There are a number of hydrophobic and polar interactions established by the substrate with its putative binding site (Fig.  5b) . The stabilization of the substrate in the binding pocket is predicted to be achieved partly through van der Waals contacts with the non-polar sidechains of Trp 34 . Among these, Trp 34 forms a parallel stacking interaction with the substrate 4-hydroxy-D-phenylglycine moiety at substrate residue 4 (Fig. 5b) . The Trp34Phe mutant enzyme shows a precipitous loss of activity (Table 2) , consistent with this model.
Several hydrophilic interactions are also predicted to contribute to substrate binding (Fig. 5b) . Notably, the reactive phenolic hydroxyl at residue 1 (4-hydroxy-Lphenylglycine) of desulfo-A47934 is well positioned for in-line attack at the sulfate group of PAPS, and is hydrogen bonded to the imidazole ring of His 67 , which is predicted to abstract the phenolic proton. Moreover, a hydrogen bonding interaction is established between the amino group at residue 1 of desulfo-A47934 and the mainchain carbonyl of Ile
131
. At the other end of the substrate molecule, a hydroxyl group of the 3,5-dihydroxyphenylglycine (DHPG) residue 7 forms hydrogen bonds with both the mainchain and sidechain of Ser
98
, and potentially also with the 3'-phosphate group of PAPS. Mutation of Ser 98 to Ala removes the H-bond donor and results in a 60% drop in activity ( (Table 2) . Although the loop 217-235 of StaL was not modeled, it is expected to be located close to where the substrate docks.
Putative catalytic residues
Sulfonation of the phenolic hydroxyl group of the N-terminal 4-hydroxy-Lphenylglycine of the antibiotic requires deprotonation of this group. The pKa of the phenolic hydroxyl group is not known, however, it is expected to be similar to Tyr (pK a ~9-10). In any event, the enzyme would be required to either bind the deprotonated form of the antibiotic substrate or assist in the removal of the target phenolic hydroxyl. There are two well-positioned residues, His 43 (Table 2) , while His67Ala mutant expressed poorly and could not be purified (see below). Given the structural and mutagenesis data, we favor the molecular mechanism of antibiotic sulfation shown in Fig. 6 (Fig. 5) . Structurallyequivalent residues have been proposed to be important in catalysis in other sulfotransferases (reviewed in (11) ). The lysine and serine residues, which play important roles in positioning and stabilizing the PAPS molecule, are conserved in both cytosolic and Golgi-resident sulfotransferases. It is plausible that these two residues in StaL play similar roles. The structurally equivalent residues in the mycobacterial sulfotransferase 
A novel mode of dimerization of STs
Almost all eukaryotic cytosolic sulfotransferases are homodimers in their catalytically-active forms, with mEST being one of the few exceptions (10;51). Structural comparisons and mutagenesis studies have demonstrated that these proteins share a conserved dimerization interface represented by the consensus sequence KX 3 TVX 3 E, designated the KTVE motif, located near the C-terminus (51 (Fig.  7) . In contrast to a relatively small buried surface area (~3%) for human hydroxysteroid sulfotransferase (hHST) and other cytosolic STs (51), the buried surface area of the interface in StaL is ~800 Å 2 per monomer, approximately 6.5% of the total surface. The residues we have identified at the StaL dimerization interface bear no similarity to those of the eukaryotic cytosolic ST dimers (Fig.7b) In some sulfotransferase structures, the enzymes crystallize as dimers, although these dimers are unlikely to represent the active form since the putative substrate-binding site is blocked by the dimer interface (46;52). There is no indication from the structure of the StaL dimer that its dimeric nature would negatively influence access to the substrate, as reflected by our modeling results. Despite the relatively small number of residues (~15) involved in the dimerization interface, the overall interactions are extensive in this region, with more than ten hydrogen bonds formed between residues of the two monomers (Fig.  7c) . The formation of the dimer is also driven by numerous hydrophobic contacts. For example, Leu 48 , situated in the middle part of the interface, interacts with its counterpart residue from the second monomer. Similarly, Phe 77 , located at the edge of the interface, stacks against the same residue from the second monomer.
Based on analysis and comparison of the StaL structures, two residues located at the dimer interface, Leu 48 and Phe
77
, were mutated in order to assess the contribution of these residues to dimerization. The mutants Leu48Arg and Leu48Glu resulted in lower protein expression and solubility, which were detrimental to purification of the proteins. These results suggest that Leu 48 plays an important role in protein stability, which may rely on formation of the dimer. The Phe77Glu variant was readily produced and purified using the same protocol as for wild-type StaL, with no significant differences observed in its expression level. Gel filtration experiments showed that it still forms dimers in solution. Nevertheless, its enzymatic activity was significantly reduced, with <10% activity for the substrate desulfo-A47934 compared with wild-type StaL (Table 2) . It is evident therefore that Phe 77 , a residue far from the active site, is necessary for maximum activity, although it is not essential for dimer formation.
CONCLUSIONS
The crystal structure shows that StaL, the final enzyme in the A47934 antibiotic biosynthetic pathway, is more similar to the mammalian cytosolic sulfotransferases than to the bacterial sulfotransferase Stf0. The complex with PAP showed that the cofactor binding site is similar to that in other STs. However, the substrate binding site is more open and guarded by a long and flexible loop, which presumably plays a role in holding and release of the substrate. While we could not obtain the structure of the StaL-PAP-substrate complex we have used molecular modeling to predict the desulfo-A47934 binding mode and through site-directed mutagenesis confirmed the impact on enzymatic activity of residues predicted to be involved in substrate binding. This enzyme may have potential application in expanding the repertoire of engineering possibilities for developing novel glycopeptide antibiotics. representation of StaL with the desulfo-A47934 (substrate) and PAPS (cofactor) shown in stick representation. The PAPS was modeled on the PAP present in our crystal structure. Desulfo-A47934 was modeled as described in the text (colors: C -green, Ored, N -blue, Cl -cyan). The concave surface of desulfo-A47934 packs against the bottom of the binding pocket while its convex surface is exposed to the solvent but likely covered by the loop that is disordered in our crystal structure; b) The active site of StaL with modeled desulfo-A47934 and PAPS. The substrate is colored as above while the protein C atoms are painted white. The hydroxyl group of desulfo-A47934 to be sulfonated is marked by a red sphere. Using desulfo-A47934 as a substrate, the initial rate was determined for each mutant and was compared to wild-type StaL. b ND = Not Determined. These mutants did not express well and were not tested. Figure 1 
